One-liner: Abzu develops trustworthy and explainable AI solutions for the pharmaceutical R&D sector.
Company slogan: Abzu is the best in class in silico disease understanding and drug design company.
Positioning: “Abzu is positioned as a provider of trustworthy and explainable AI specifically tailored for the pharmaceutical R&D sector, emphasizing its unique capabilities in data analysis and insights generation.”
Description: “Abzu is the best in class in silico disease understanding and drug design company. Since its founding in 2018, Abzu’s proprietary explainable AI, the QLattice®, has been the cornerstone to their cutting-edge approach. Abzu is a preferred partner for pharma, biotech, and research institutions, transforming data into insights and accelerating R&D.
Abzu has offices in Copenhagen and Barcelona, and has raised €13.3M in total funding to date. Abzu has been mentioned in Gartner® research, from Market Guides for AI Trust, Risk, and Security Management to Cool Vendor™, and is the winner of several awards, including the 2023 “Best HealthTech” Nordics Award at the Nordic Startup Awards.”
Employees: 27
Website: Visit websiteHeadquarters: “Nordhavn, Capital Region”
Ownership: Privately Held
Founded: 2018
Company type: AI company
Use cases: “pharma R&D, drug design, understanding disease, RNA therapeutics”
Pricing: –
Client sector: pharmaceutical industry
Business model: subscription
Products: QLattice
Is API available: no
Website title: “Abzu: Trustworthy, explainable AI for pharma R&D.”
Website description: “Abzu’s AI is built for the modern researcher, where explainability, small data, and new insights are at the core of innovative discoveries.”
Linkedin: https://www.linkedin.com/company/abzu/
Youtube: https://www.youtube.com/@abzu_ai
Instagram: https://www.instagram.com/abzu_ai/
Facebook: –
Twitter: https://twitter.com/AbzuAI
Crunchbase: https://www.crunchbase.com/organization/abzu
Email: –